Cancer Care Adds Ovarian Cancer Section to Website

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 8
Volume 7
Issue 8

NEW YORK--Cancer Care, Inc. has launched a new online resource for ovarian cancer patients and their families and friends. A new section added to Cancer Care’s website (www.cancercare.org) offers a comprehensive overview of ovarian cancer and a resource guide.

NEW YORK--Cancer Care, Inc. has launched a new online resource for ovarian cancer patients and their families and friends. A new section added to Cancer Care’s website (www.cancercare.org) offers a comprehensive overview of ovarian cancer and a resource guide.

The new addition to the website is made possible through an educational grant from SmithKline Beecham Oncology. The ovarian cancer section complements Cancer Care’s other website sections on specific types of cancer such as breast, prostate, lung, colon, brain, and melanoma.

Information provided about the disease includes tumor differentiation and staging, risk factors, coping, and diagnostic and treatment options. Answers to common questions about ovarian cancer are also included.

"We wanted ovarian cancer patients to be able to address any technical or practical concerns they have regarding the disease," said Diane Blum, MSW, executive director of Cancer Care. "This website section, as with all of Cancer Care’s website sections, encourages patients to utilize all available resources for their medical, emotional, and financial needs. We believe it will help connect patients with essential resources."

Related Videos
Interim data reveal favorable responses in patients with low-grade serous ovarian cancer treated with avutometinib plus defactinib, according to Susana N. Banerjee, MD.
Treatment with mirvetuximab soravtansine appears to produce a 3-fold improvement in objective response rate vs chemotherapy among patients with folate receptor-α–expressing, platinum-resistant ovarian cancer in the phase 3 MIRASOL trial.
PRGN-3005 autologous UltraCAR-T cells appear well-tolerated and decreases tumor burden in a population of patients with advanced platinum-resistant ovarian cancer.
An expert from Dana-Farber Cancer Institute discusses findings from the final overall survival analysis of the phase 3 ENGOT-OV16/NOVA trial.